Investing.comDoubao · 实盘不做把握 6/10不做原因:风险收益比不佳
北京时间·🕒 发布 05:03:05·⟳ 抓取 05:03:26 +21s·⚡ 决策 10-22 05:21:36 +18m10s·5.9 天前
Medpace（MEDP.US）Q3业绩超预期但全年收入指引中点略低于预期，盘后剧烈震荡
MIXED财报：EPS/营收双beat、GAAP EPS指引高于预期、新增订单+10.6%及10亿美元回购（相对185亿美元市值约5.4%）构成支撑，但全年收入指引中点仅低于预期约0.25%、不构成强空催化；正股财报当日已放量抢跑+6.43%（量比3.69）逼近历史高位，盘后从-11%到+1%剧烈双向波动（590–668美元），消息真实但多空双方均已在剧烈重定价，次日开盘方向不可预判，无正期望edge。
📄 原文Investing.com↗ 原文
Medpace beats Q3 estimates but guides below on revenue
Nasdaq surges 1% as tech lifted by SpaceX, Tesla on Musk’s hint at possible merger Investing.com -- Medpace Holdings In…
不做 Medpace Holdings Inc（MEDP.US）
MIXED财报多空对冲：EPS/营收beat+GAAP EPS指引超预期+订单增长+10亿美元回购 vs 收入指引中点微低0.25%；正股财报当日已放量抢跑6.43%、处于历史高位附近，盘后自-11%到+1%剧烈双向震荡（590–668美元），追多恐利好兑现、做空无强催化且有大额回购托底，两侧均无正期望edge，且盘后不可成交、次日开盘方向不可预判。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Medpace Q3业绩beat且新批10亿美元回购，但全年收入指引中点微低于预期，属多空对冲的MIXED财报；正股当日已放量抢跑6.4%、盘后巨幅震荡，追多面临利好兑现、做空面对基本面beat和大额回购托底，两侧均无edge，不做。
🔎 新鲜度:最早出现 2026-10-21 · 扩散 medium · price-in 风险 high ↗
关键理由
- EPS超预期9%、GAAP EPS指引中点高于预期、订单与积压双增且回购授权扩大近一倍，基本面不支持趋势性做空
- 收入指引中点仅低预期0.25%、属轻微miss而非指引下修，且正股已抢跑6.4%，盘后最初-1.9%的反应不构成可持续做空催化
主要风险
- 正股财报当日放量大涨6.4%或为预期/泄露抢跑，盘后一度自高点回落超11%，次日可能高开低走，做多承接风险大
- 业绩电话会若释放2027年需求或订单转化放缓信号，盘后反弹可能逆转；反之则盘后低点成为错杀，两侧都依赖尚未落地的电话会信息
反向证据
- 做多前查反向 · 来源 web · 日期 2026-10-21 · 影响 weakens
全年收入指引中点28.45亿低于一致预期28.52亿，且正股当日已抢跑6.43%、报道时盘后下跌，构成做多的直接反证。
检索:Medpace FY2026 revenue guidance below consensus guidance miss 原文 ↗ - 做空前查反向 · 来源 web · 日期 2026-10-21 · 影响 weakens
EPS超预期9%、GAAP EPS指引中点高于预期、新签订单+10.6%、积压+5.6%、10亿美元回购授权（占市值约5.4%），收入指引仅微低0.25%而非下修，做空面对强基本面与回购托底。
检索:Medpace Q3 EPS beat $1 billion buyback net new business awards backlog growth 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例与盘后行为均支持AVOID：不给方向性交易，不设tp/sl。
方向:未构建外部先例面板：本事件为MIXED财报（beat+大额回购 vs 收入指引微miss+当日抢跑6.4%），同机制近期案例（如GM 10月20日beat+200亿美元回购但指引担忧，盘后至盘中跌5-7%）同样指向多空对冲、无edge，但该案例来自已处理库而非首发溯源的外部先例，不作为定量依据。
涨幅量级:无高相似对齐先例校准幅度；盘后实际区间（自收盘-11%至+1%）本身即显示幅度不可靠。
形态:盘后先杀至590美元再拉回653美元的双向巨震，是典型的MIXED财报流动性博弈，方向未定，不支持追任一侧。
工具执行结果 · 成功 2 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 4,183 ms
{"result": "search_processed_events:agent query=`medp full-year 2026 revenue outlook lowered | medpace medp q3 2026 earnings revenue guidance | medpace third quarter results eps beat buyback $1 billion`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 72.0/72 小时、27227 条本臂决策(完整)，返回 2 条候选。\n• 10-20 11:08 UTC(北京 19:08) [bm25: - stock_quote 成功 stock_tools HTTP · 683 ms
{
原文全文
展开原文 · 1,978 字
Nasdaq surges 1% as tech lifted by SpaceX, Tesla on Musk’s hint at possible merger
Investing.com -- Medpace Holdings Inc (NASDAQ:MEDP) reported third quarter results that exceeded analyst expectations, but shares slipped 1.9% in after-hours trading Wednesday as the company's full-year revenue guidance disappointed investors.
The clinical contract research organization posted adjusted earnings of $4.84 per share for the third quarter, beating the analyst consensus of $4.44 by $0.40. Revenue reached $716.0 million, slightly above the estimate of $714.47 million and up 8.5% from $659.9 million in the prior-year period. The company reported EBITDA of $172.1 million, representing a 24.0% margin and a 16.0% increase YoY.
For full-year 2026, Medpace issued guidance of $2.835 billion to $2.855 billion in revenue, with a midpoint of $2.845 billion falling below the analyst consensus of $2.852 billion. The company expects GAAP earnings per share of $17.97 to $18.32, with a midpoint of $18.15 that exceeds the consensus estimate of $17.72. The revenue outlook represents growth of 12.0% to 12.8% over 2025 revenue of $2.530 billion.
Net new business awards totaled $873.4 million in the quarter, up 10.6% from $789.6 million in the year-ago period. Backlog as of September 30, 2026 increased 5.6% to $3,167.2 million from $3,000.6 million a year earlier.
GAAP net income for the quarter was $137.5 million, or $4.84 per diluted share, compared to $111.1 million, or $3.86 per diluted share, in the third quarter of 2025. Net income margin expanded to 19.2% from 16.8% in the prior-year period.
The company's board approved a new $1.0 billion stock repurchase authorization effective October 20, 2026, replacing the previous program that had $527.0 million remaining. The new authorization runs through December 31, 2028.
Medpace generated $216.6 million in operating cash flow during the quarter and held $705.3 million in cash and cash equivalents as of September 30, 2026.
Investing.com -- Medpace Holdings Inc (NASDAQ:MEDP) reported third quarter results that exceeded analyst expectations, but shares slipped 1.9% in after-hours trading Wednesday as the company's full-year revenue guidance disappointed investors.
The clinical contract research organization posted adjusted earnings of $4.84 per share for the third quarter, beating the analyst consensus of $4.44 by $0.40. Revenue reached $716.0 million, slightly above the estimate of $714.47 million and up 8.5% from $659.9 million in the prior-year period. The company reported EBITDA of $172.1 million, representing a 24.0% margin and a 16.0% increase YoY.
For full-year 2026, Medpace issued guidance of $2.835 billion to $2.855 billion in revenue, with a midpoint of $2.845 billion falling below the analyst consensus of $2.852 billion. The company expects GAAP earnings per share of $17.97 to $18.32, with a midpoint of $18.15 that exceeds the consensus estimate of $17.72. The revenue outlook represents growth of 12.0% to 12.8% over 2025 revenue of $2.530 billion.
Net new business awards totaled $873.4 million in the quarter, up 10.6% from $789.6 million in the year-ago period. Backlog as of September 30, 2026 increased 5.6% to $3,167.2 million from $3,000.6 million a year earlier.
GAAP net income for the quarter was $137.5 million, or $4.84 per diluted share, compared to $111.1 million, or $3.86 per diluted share, in the third quarter of 2025. Net income margin expanded to 19.2% from 16.8% in the prior-year period.
The company's board approved a new $1.0 billion stock repurchase authorization effective October 20, 2026, replacing the previous program that had $527.0 million remaining. The new authorization runs through December 31, 2028.
Medpace generated $216.6 million in operating cash flow during the quarter and held $705.3 million in cash and cash equivalents as of September 30, 2026.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
dce0e55adb· 2026-10-22 05:21 · doubao / doubao-seed-evolving-latest-version · 策略包658c0c1e2ba5当前